Corcept Therapeutics Incorporated (CORT NASDAQ) stock market data APIs
$51.1616
0.81(1.6%)
as of May 7, 2026
Try our APIs with
free plan!
Corcept Therapeutics Incorporated Financial Data Overview
Price chart is built with
Anychart
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Prev. Close
51.1616
Open
51.9667
High
53.1401
Low
50.18
52 wk Range
28.66-91
Market Cap
5 480 M
P/E Ratio
145.8572
Shares Outstanding
107 M
Revenue
769 M
EPS
-0.3
Beta
0.355
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Corcept Therapeutics Incorporated (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Corcept Therapeutics Incorporated data using free add-ons & libraries
Get Corcept Therapeutics Incorporated Fundamental Data
Corcept Therapeutics Incorporated Fundamental data includes:
- Net Revenue: 769 M
- EBITDA: -6 935 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Corcept Therapeutics Incorporated Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-06
- EPS/Forecast: -0.1513
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corcept Therapeutics Incorporated News
New
Corcept Therapeutics (CORT) Is Up 11.9% After Q1 Loss, Higher 2026 Outlook And ALS Data - Has The Bull Case Changed?
In late April 2026, Corcept Therapeutics reported a first-quarter net loss of US$31.76 million versus net income of US$20.55 million a year earlier, while simultaneously raising its 2026 revenue outlo...
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million. On the other hand, the company’s full...
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli
Corcept Therapeutics Incorporated (NASDAQ:CORT) ranks among the most profitable biotech stocks to buy now. At the Society of Gynecologic Oncology Annual Meeting on April 10, Corcept Therapeutics Incor...
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Corcept Therapeutics CORT incurred a first-quarter 2026 loss of 30 cents per share, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had reported earnings of 17 cents pe...
Get Corcept Therapeutics Incorporated fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
